BACKGROUND The efficacy and safety of transarterial chemoembolization(TACE)combined with lenvatinib plus programmed cell death protein-1(PD-1)for unresectable hepato-cellular carcinoma(HCC)have rarely been evaluated a...BACKGROUND The efficacy and safety of transarterial chemoembolization(TACE)combined with lenvatinib plus programmed cell death protein-1(PD-1)for unresectable hepato-cellular carcinoma(HCC)have rarely been evaluated and it is unknown which factors are related to efficacy.AIM To evaluate the efficacy and independent predictive factors of TACE combined with lenvatinib plus PD-1 inhibitors for unresectable HCC.METHODS This study retrospectively enrolled patients with unresectable HCC who received TACE/lenvatinib/PD-1 treatment between March 2019 and April 2022.Overall survival(OS)and progression-free survival(PFS)were determined.The objective response rate(ORR)and disease control rate(DCR)were evaluated in accordance with the modified Response Evaluation Criteria in Solid Tumors.Additionally,the prognostic factors affecting the clinical outcome were assessed.RESULTS One hundred and two patients were enrolled with a median follow-up duration of 12.63 months.The median OS was 26.43 months(95%CI:17.00-35.87),and the median PFS was 10.07 months(95%CI:8.50-11.65).The ORR and DCR were 61.76%and 81.37%,respectively.The patients with Barcelona Clinic Liver Cancer Classification(BCLC)B stage,early neutrophil-to-lymphocyte ratio(NLR)response(decrease),or early alpha-fetoprotein(AFP)response(decrease>20%)had superior OS and PFS than their counterparts.CONCLUSION This study showed that TACE/lenvatinib/PD-1 treatment was well tolerated with encouraging efficacy in patients with unresectable HCC.The patients with BCLC B-stage disease with early NLR response(decrease)and early AFP response(decrease>20%)may achieve better clinical outcomes with this triple therapy.展开更多
To the Editor:Hepatocellular carcinoma(HCC)is the third most lethal malignancy globally.[1]Besides sorafenib,lenvatinib is currently the second approved targeted agent for the first-line treatment of HCC in 2018.Lenva...To the Editor:Hepatocellular carcinoma(HCC)is the third most lethal malignancy globally.[1]Besides sorafenib,lenvatinib is currently the second approved targeted agent for the first-line treatment of HCC in 2018.Lenvatinib is an oral multikinase inhibitor that targets vascular endothelial growth factor(VEGF)receptors 1 to 3,fibroblast growth factor receptors 1 to 4,platelet-derived growth factor receptor a,RET,and KIT.[2]Patients who received lenvatinib experienced diarrhoea,and alope and more instances of hypertension,proteinuria,and hypothyroidism.Here,we report two patients that developed irreversible pancreatic atrophy as a novel adverse event of lenvatinib.展开更多
文摘BACKGROUND The efficacy and safety of transarterial chemoembolization(TACE)combined with lenvatinib plus programmed cell death protein-1(PD-1)for unresectable hepato-cellular carcinoma(HCC)have rarely been evaluated and it is unknown which factors are related to efficacy.AIM To evaluate the efficacy and independent predictive factors of TACE combined with lenvatinib plus PD-1 inhibitors for unresectable HCC.METHODS This study retrospectively enrolled patients with unresectable HCC who received TACE/lenvatinib/PD-1 treatment between March 2019 and April 2022.Overall survival(OS)and progression-free survival(PFS)were determined.The objective response rate(ORR)and disease control rate(DCR)were evaluated in accordance with the modified Response Evaluation Criteria in Solid Tumors.Additionally,the prognostic factors affecting the clinical outcome were assessed.RESULTS One hundred and two patients were enrolled with a median follow-up duration of 12.63 months.The median OS was 26.43 months(95%CI:17.00-35.87),and the median PFS was 10.07 months(95%CI:8.50-11.65).The ORR and DCR were 61.76%and 81.37%,respectively.The patients with Barcelona Clinic Liver Cancer Classification(BCLC)B stage,early neutrophil-to-lymphocyte ratio(NLR)response(decrease),or early alpha-fetoprotein(AFP)response(decrease>20%)had superior OS and PFS than their counterparts.CONCLUSION This study showed that TACE/lenvatinib/PD-1 treatment was well tolerated with encouraging efficacy in patients with unresectable HCC.The patients with BCLC B-stage disease with early NLR response(decrease)and early AFP response(decrease>20%)may achieve better clinical outcomes with this triple therapy.
基金This work was supported by a grant from the Big Data Research and Development Project of the General Hospital of People's Liberation Army(No.2018MBD-011).
文摘To the Editor:Hepatocellular carcinoma(HCC)is the third most lethal malignancy globally.[1]Besides sorafenib,lenvatinib is currently the second approved targeted agent for the first-line treatment of HCC in 2018.Lenvatinib is an oral multikinase inhibitor that targets vascular endothelial growth factor(VEGF)receptors 1 to 3,fibroblast growth factor receptors 1 to 4,platelet-derived growth factor receptor a,RET,and KIT.[2]Patients who received lenvatinib experienced diarrhoea,and alope and more instances of hypertension,proteinuria,and hypothyroidism.Here,we report two patients that developed irreversible pancreatic atrophy as a novel adverse event of lenvatinib.
